论文部分内容阅读
目的探讨阿立哌唑治疗氟哌啶醇所致女性高催乳素血症的疗效及安全性。方法将60例氟哌啶醇所致高催乳素血症的女性精神分裂症患者,随机分为两组,在维持原氟哌啶醇治疗的同时,分别加阿立哌唑(30例)及安慰剂(30例)治疗,疗程6周。分别于治疗前、治疗6周末检测血清催乳素(PRL)水平、评定简明精神病量表(BPRS)及副反应量表(TESS),同时观察高催乳素血症临床症状变化情况。结果1治疗6周末,阿立哌唑组PRL26.1±9.4μg/L较治疗前99.4±31.3μg/L下降(P=0.000),安慰剂组PRL91.3±38.3μg/L与治疗前96.9±30.8μg/L无显著性差异(P=0.230);2治疗6周末,阿立哌唑组PRL下降值73.2±27.2μg/L高于安慰剂组5.7±25.3μg/L,差异有显著性(P=0.000);3两组不良反应总体发生率均低,对原氟哌啶醇治疗的疗效均无不良影响。结论阿立哌唑可安全、有效治疗氟哌啶醇所致的女性高催乳素血症。
Objective To investigate the efficacy and safety of aripiprazole in the treatment of haloperidol-induced female hyperprolactinemia. Methods Sixty female schizophrenia patients with hyperprolactinemia induced by haloperidol were randomly divided into two groups. Aripiprazole (30 cases) and control group Placebo (30 cases) treatment, treatment for 6 weeks. Serum prolactin (PRL) levels were measured before treatment and at the end of 6 weeks of treatment, and the BPRS and TESS were assessed. The clinical symptoms of hyperprolactinemia were also observed. Results 1 After 6 weeks of treatment, PRL26.1 ± 9.4μg / L in aripiprazole group was lower than 99.4 ± 31.3μg / L before treatment (P = 0.000), PRL was 91.3 ± 38.3μg / L in placebo group and 96.9 (P = 0.230) .2 After 6 weeks of treatment, the decrease of PRL in aripiprazole group was 73.2 ± 27.2μg / L than that in placebo group (5.7 ± 25.3μg / L), the difference was significant (P = 0.000) .3 The overall incidence of adverse reactions in both groups was low, and had no adverse effect on the efficacy of the original haloperidol treatment. Conclusion Aripiprazole can be safely and effectively treated with haloperidol in women with hyperprolactinemia.